Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16 entries
Sorted by: Best Match Show Resources per page
Development and Validation of an Early Scoring System for Prediction of Disease Severity in COVID-19 Using Complete Blood Count Parameters.

IEEE access : practical innovations, open solutions

Rahman T, Khandakar A, Hoque ME, Ibtehaz N, Kashem SB, Masud R, Shampa L, Hasan MM, Islam MT, Al-Maadeed S, Zughaier SM, Badran S, Doi SAR, Chowdhury MEH.
PMID: 34786318
IEEE Access. 2021 Aug 16;9:120422-120441. doi: 10.1109/ACCESS.2021.3105321. eCollection 2021.

The coronavirus disease 2019 (COVID-19) after outbreaking in Wuhan increasingly spread throughout the world. Fast, reliable, and easily accessible clinical assessment of the severity of the disease can help in allocating and prioritizing resources to reduce mortality. The objective...

Cite
Rahman T, Khandakar A, Hoque ME, et al. Development and Validation of an Early Scoring System for Prediction of Disease Severity in COVID-19 Using Complete Blood Count Parameters. IEEE Access. 2021;9:120422-120441doi: 10.1109/ACCESS.2021.3105321.
Rahman, T., Khandakar, A., Hoque, M. E., Ibtehaz, N., Kashem, S. B., Masud, R., Shampa, L., Hasan, M. M., Islam, M. T., Al-Maadeed, S., Zughaier, S. M., Badran, S., Doi, S. A. R., & Chowdhury, M. E. H. (2021). Development and Validation of an Early Scoring System for Prediction of Disease Severity in COVID-19 Using Complete Blood Count Parameters. IEEE access : practical innovations, open solutions, 9120422-120441. https://doi.org/10.1109/ACCESS.2021.3105321
Rahman, Tawsifur, et al. "Development and Validation of an Early Scoring System for Prediction of Disease Severity in COVID-19 Using Complete Blood Count Parameters." IEEE access : practical innovations, open solutions vol. 9 (2021): 120422-120441. doi: https://doi.org/10.1109/ACCESS.2021.3105321
Rahman T, Khandakar A, Hoque ME, Ibtehaz N, Kashem SB, Masud R, Shampa L, Hasan MM, Islam MT, Al-Maadeed S, Zughaier SM, Badran S, Doi SAR, Chowdhury MEH. Development and Validation of an Early Scoring System for Prediction of Disease Severity in COVID-19 Using Complete Blood Count Parameters. IEEE Access. 2021 Aug 16;9:120422-120441. doi: 10.1109/ACCESS.2021.3105321. eCollection 2021. PMID: 34786318; PMCID: PMC8545188.
Copy Download .nbib Format: NLM
An Early Warning Tool for Predicting Mortality Risk of COVID-19 Patients Using Machine Learning.

Cognitive computation

Chowdhury MEH, Rahman T, Khandakar A, Al-Madeed S, Zughaier SM, Doi SAR, Hassen H, Islam MT.
PMID: 33897907
Cognit Comput. 2021 Apr 21;1-16. doi: 10.1007/s12559-020-09812-7. Epub 2021 Apr 21.

COVID-19 pandemic has created an extreme pressure on the global healthcare services. Fast, reliable, and early clinical assessment of the severity of the disease can help in allocating and prioritizing resources to reduce mortality. In order to study the...

Cite
Chowdhury MEH, Rahman T, Khandakar A, et al. An Early Warning Tool for Predicting Mortality Risk of COVID-19 Patients Using Machine Learning. Cognit Comput. 2021;1-16doi: 10.1007/s12559-020-09812-7.
Chowdhury, M. E. H., Rahman, T., Khandakar, A., Al-Madeed, S., Zughaier, S. M., Doi, S. A. R., Hassen, H., & Islam, M. T. (2021). An Early Warning Tool for Predicting Mortality Risk of COVID-19 Patients Using Machine Learning. Cognitive computation, 1-16. https://doi.org/10.1007/s12559-020-09812-7
Chowdhury, Muhammad E H, et al. "An Early Warning Tool for Predicting Mortality Risk of COVID-19 Patients Using Machine Learning." Cognitive computation vol. (2021): 1-16. doi: https://doi.org/10.1007/s12559-020-09812-7
Chowdhury MEH, Rahman T, Khandakar A, Al-Madeed S, Zughaier SM, Doi SAR, Hassen H, Islam MT. An Early Warning Tool for Predicting Mortality Risk of COVID-19 Patients Using Machine Learning. Cognit Comput. 2021 Apr 21;1-16. doi: 10.1007/s12559-020-09812-7. Epub 2021 Apr 21. PMID: 33897907; PMCID: PMC8058759.
Copy Download .nbib Format: NLM
The Effects of First-Line Anti-Tuberculosis Drugs on the Actions of Vitamin D in Human Macrophages.

Journal of clinical & translational endocrinology

Chesdachai S, Zughaier SM, Hao L, Kempker RR, Blumberg HM, Ziegler TR, Tangpricha V.
PMID: 28111615
J Clin Transl Endocrinol. 2016 Dec;6:23-29. doi: 10.1016/j.jcte.2016.08.005.

Tuberculosis (TB) is a major global health problem. Patients with TB have a high rate of vitamin D deficiency, both at diagnosis and during the course of treatment with anti-tuberculosis drugs. Although data on the efficacy of vitamin D...

Cite
Chesdachai S, Zughaier SM, Hao L, et al. The Effects of First-Line Anti-Tuberculosis Drugs on the Actions of Vitamin D in Human Macrophages. J Clin Transl Endocrinol. 2016;6:23-29doi: 10.1016/j.jcte.2016.08.005.
Chesdachai, S., Zughaier, S. M., Hao, L., Kempker, R. R., Blumberg, H. M., Ziegler, T. R., & Tangpricha, V. (2016). The Effects of First-Line Anti-Tuberculosis Drugs on the Actions of Vitamin D in Human Macrophages. Journal of clinical & translational endocrinology, 623-29. https://doi.org/10.1016/j.jcte.2016.08.005
Chesdachai, Supavit, et al. "The Effects of First-Line Anti-Tuberculosis Drugs on the Actions of Vitamin D in Human Macrophages." Journal of clinical & translational endocrinology vol. 6 (2016): 23-29. doi: https://doi.org/10.1016/j.jcte.2016.08.005
Chesdachai S, Zughaier SM, Hao L, Kempker RR, Blumberg HM, Ziegler TR, Tangpricha V. The Effects of First-Line Anti-Tuberculosis Drugs on the Actions of Vitamin D in Human Macrophages. J Clin Transl Endocrinol. 2016 Dec;6:23-29. doi: 10.1016/j.jcte.2016.08.005. PMID: 28111615; PMCID: PMC5242622.
Copy Download .nbib Format: NLM
Pyoverdine, the Major Siderophore in Pseudomonas aeruginosa, Evades NGAL Recognition.

Interdisciplinary perspectives on infectious diseases

Peek ME, Bhatnagar A, McCarty NA, Zughaier SM.
PMID: 22973307
Interdiscip Perspect Infect Dis. 2012;2012:843509. doi: 10.1155/2012/843509. Epub 2012 Sep 02.

Pseudomonas aeruginosa is the most common pathogen that persists in the cystic fibrosis lungs. Bacteria such as P. aeruginosa secrete siderophores (iron-chelating molecules) and the host limits bacterial growth by producing neutrophil-gelatinase-associated lipocalin (NGAL) that specifically scavenges bacterial siderophores,...

Cite
Peek ME, Bhatnagar A, McCarty NA, et al. Pyoverdine, the Major Siderophore in Pseudomonas aeruginosa, Evades NGAL Recognition. Interdiscip Perspect Infect Dis. 2012;2012:843509doi: 10.1155/2012/843509.
Peek, M. E., Bhatnagar, A., McCarty, N. A., & Zughaier, S. M. (2012). Pyoverdine, the Major Siderophore in Pseudomonas aeruginosa, Evades NGAL Recognition. Interdisciplinary perspectives on infectious diseases, 2012843509. https://doi.org/10.1155/2012/843509
Peek, Mary E, et al. "Pyoverdine, the Major Siderophore in Pseudomonas aeruginosa, Evades NGAL Recognition." Interdisciplinary perspectives on infectious diseases vol. 2012 (2012): 843509. doi: https://doi.org/10.1155/2012/843509
Peek ME, Bhatnagar A, McCarty NA, Zughaier SM. Pyoverdine, the Major Siderophore in Pseudomonas aeruginosa, Evades NGAL Recognition. Interdiscip Perspect Infect Dis. 2012;2012:843509. doi: 10.1155/2012/843509. Epub 2012 Sep 02. PMID: 22973307; PMCID: PMC3438788.
Copy Download .nbib Format: NLM
Structure-Dependent Immune Modulatory Activity of Protegrin-1 Analogs.

Antibiotics (Basel, Switzerland)

Zughaier SM, Svoboda P, Pohl J.
PMID: 26097747
Antibiotics (Basel). 2014 Dec;3(4):694-713. doi: 10.3390/antibiotics3040694.

Protegrins are porcine antimicrobial peptides (AMPs) that belong to the cathelicidin family of host defense peptides. Protegrin-1 (PG-1), the most investigated member of the protegrin family, is an arginine-rich peptide consisting of 18 amino acid residues, its main chain...

Cite
Zughaier SM, Svoboda P, Pohl J. Structure-Dependent Immune Modulatory Activity of Protegrin-1 Analogs. Antibiotics (Basel). 2014;3(4):694-713doi: 10.3390/antibiotics3040694.
Zughaier, S. M., Svoboda, P., & Pohl, J. (2014). Structure-Dependent Immune Modulatory Activity of Protegrin-1 Analogs. Antibiotics (Basel, Switzerland), 3(4), 694-713. https://doi.org/10.3390/antibiotics3040694
Zughaier, Susu M, et al. "Structure-Dependent Immune Modulatory Activity of Protegrin-1 Analogs." Antibiotics (Basel, Switzerland) vol. 3,4 (2014): 694-713. doi: https://doi.org/10.3390/antibiotics3040694
Zughaier SM, Svoboda P, Pohl J. Structure-Dependent Immune Modulatory Activity of Protegrin-1 Analogs. Antibiotics (Basel). 2014 Dec;3(4):694-713. doi: 10.3390/antibiotics3040694. PMID: 26097747; PMCID: PMC4472440.
Copy Download .nbib Format: NLM
The Role of Soluble Uric Acid in Modulating Autophagy Flux and Inflammasome Activation during Bacterial Infection in Macrophages.

Biomedicines

Al-Awad D, Al-Emadi N, Abu-Madi M, Al-Thani AA, Zughaier SM.
PMID: 33322651
Biomedicines. 2020 Dec 12;8(12). doi: 10.3390/biomedicines8120598.

Autophagy is a homeostatic process that regulates and recycles intracellular structures and is a host defense mechanism that facilitates bacterial clearance. Uric acid in plasma is a major antioxidant but in certain conditions acts as an inflammatory danger signal....

Cite
Al-Awad D, Al-Emadi N, Abu-Madi M, et al. The Role of Soluble Uric Acid in Modulating Autophagy Flux and Inflammasome Activation during Bacterial Infection in Macrophages. Biomedicines. 2020;8(12)doi: 10.3390/biomedicines8120598.
Al-Awad, D., Al-Emadi, N., Abu-Madi, M., Al-Thani, A. A., & Zughaier, S. M. (2020). The Role of Soluble Uric Acid in Modulating Autophagy Flux and Inflammasome Activation during Bacterial Infection in Macrophages. Biomedicines, 8(12), . https://doi.org/10.3390/biomedicines8120598
Al-Awad, Duha, et al. "The Role of Soluble Uric Acid in Modulating Autophagy Flux and Inflammasome Activation during Bacterial Infection in Macrophages." Biomedicines vol. 8,12 (2020). doi: https://doi.org/10.3390/biomedicines8120598
Al-Awad D, Al-Emadi N, Abu-Madi M, Al-Thani AA, Zughaier SM. The Role of Soluble Uric Acid in Modulating Autophagy Flux and Inflammasome Activation during Bacterial Infection in Macrophages. Biomedicines. 2020 Dec 12;8(12). doi: 10.3390/biomedicines8120598. PMID: 33322651; PMCID: PMC7763195.
Copy Download .nbib Format: NLM
Novel Whole-Cell Inactivated .

Vaccines

Gala RP, Zaman RU, D'Souza MJ, Zughaier SM.
PMID: 30181504
Vaccines (Basel). 2018 Sep 04;6(3). doi: 10.3390/vaccines6030060.

No abstract available.

Cite
Gala RP, Zaman RU, D'Souza MJ, et al. Novel Whole-Cell Inactivated . Vaccines (Basel). 2018;6(3)doi: 10.3390/vaccines6030060.
Gala, R. P., Zaman, R. U., D'Souza, M. J., & Zughaier, S. M. (2018). Novel Whole-Cell Inactivated . Vaccines, 6(3), . https://doi.org/10.3390/vaccines6030060
Gala, Rikhav P, et al. "Novel Whole-Cell Inactivated ." Vaccines vol. 6,3 (2018). doi: https://doi.org/10.3390/vaccines6030060
Gala RP, Zaman RU, D'Souza MJ, Zughaier SM. Novel Whole-Cell Inactivated . Vaccines (Basel). 2018 Sep 04;6(3). doi: 10.3390/vaccines6030060. PMID: 30181504; PMCID: PMC6161099.
Copy Download .nbib Format: NLM
Prevalence of asymptomatic hyperuricemia and its association with prediabetes, dyslipidemia and subclinical inflammation markers among young healthy adults in Qatar.

BMC endocrine disorders

Al Shanableh Y, Hussein YY, Saidwali AH, Al-Mohannadi M, Aljalham B, Nurulhoque H, Robelah F, Al-Mansoori A, Zughaier SM.
PMID: 35031023
BMC Endocr Disord. 2022 Jan 14;22(1):21. doi: 10.1186/s12902-022-00937-4.

AIM: The aim of this study is to investigate the prevalence of asymptomatic hyperuricemia in Qatar and to examine its association with changes in markers of dyslipidemia, prediabetes and subclinical inflammation.METHODS: A cross-sectional study of young adult participants aged...

Cite
Al Shanableh Y, Hussein YY, Saidwali AH, et al. Prevalence of asymptomatic hyperuricemia and its association with prediabetes, dyslipidemia and subclinical inflammation markers among young healthy adults in Qatar. BMC Endocr Disord. 2022;22(1):21doi: 10.1186/s12902-022-00937-4.
Al Shanableh, Y., Hussein, Y. Y., Saidwali, A. H., Al-Mohannadi, M., Aljalham, B., Nurulhoque, H., Robelah, F., Al-Mansoori, A., & Zughaier, S. M. (2022). Prevalence of asymptomatic hyperuricemia and its association with prediabetes, dyslipidemia and subclinical inflammation markers among young healthy adults in Qatar. BMC endocrine disorders, 22(1), 21. https://doi.org/10.1186/s12902-022-00937-4
Al Shanableh, Yasemin, et al. "Prevalence of asymptomatic hyperuricemia and its association with prediabetes, dyslipidemia and subclinical inflammation markers among young healthy adults in Qatar." BMC endocrine disorders vol. 22,1 (2022): 21. doi: https://doi.org/10.1186/s12902-022-00937-4
Al Shanableh Y, Hussein YY, Saidwali AH, Al-Mohannadi M, Aljalham B, Nurulhoque H, Robelah F, Al-Mansoori A, Zughaier SM. Prevalence of asymptomatic hyperuricemia and its association with prediabetes, dyslipidemia and subclinical inflammation markers among young healthy adults in Qatar. BMC Endocr Disord. 2022 Jan 14;22(1):21. doi: 10.1186/s12902-022-00937-4. PMID: 35031023.
Copy Download .nbib Format: NLM
Microneedles: A New Generation Vaccine Delivery System.

Micromachines

Menon I, Bagwe P, Gomes KB, Bajaj L, Gala R, Uddin MN, D'Souza MJ, Zughaier SM.
PMID: 33919925
Micromachines (Basel). 2021 Apr 14;12(4). doi: 10.3390/mi12040435.

Transdermal vaccination route using biodegradable microneedles is a rapidly progressing field of research and applications. The fear of painful needles is one of the primary reasons most people avoid getting vaccinated. Therefore, developing an alternative pain-free method of vaccination...

Cite
Menon I, Bagwe P, Gomes KB, et al. Microneedles: A New Generation Vaccine Delivery System. Micromachines (Basel). 2021;12(4)doi: 10.3390/mi12040435.
Menon, I., Bagwe, P., Gomes, K. B., Bajaj, L., Gala, R., Uddin, M. N., D'Souza, M. J., & Zughaier, S. M. (2021). Microneedles: A New Generation Vaccine Delivery System. Micromachines, 12(4), . https://doi.org/10.3390/mi12040435
Menon, Ipshita, et al. "Microneedles: A New Generation Vaccine Delivery System." Micromachines vol. 12,4 (2021). doi: https://doi.org/10.3390/mi12040435
Menon I, Bagwe P, Gomes KB, Bajaj L, Gala R, Uddin MN, D'Souza MJ, Zughaier SM. Microneedles: A New Generation Vaccine Delivery System. Micromachines (Basel). 2021 Apr 14;12(4). doi: 10.3390/mi12040435. PMID: 33919925; PMCID: PMC8070939.
Copy Download .nbib Format: NLM
Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial.

Dermato-endocrinology

Grossmann RE, Zughaier SM, Kumari M, Seydafkan S, Lyles RH, Liu S, Sueblinvong V, Schechter MS, Stecenko AA, Ziegler TR, Tangpricha V.
PMID: 22928076
Dermatoendocrinol. 2012 Apr 01;4(2):191-7. doi: 10.4161/derm.20332.

UNLABELLED: BACKGROUND: Vitamin D insufficiency is common in cystic fibrosis (CF) and vitamin D repletion may have an important role in improving clinical outcomes in CF. This randomized, placebo-controlled, pilot study examined the feasibility and impact of a single,...

Cite
Grossmann RE, Zughaier SM, Kumari M, et al. Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial. Dermatoendocrinol. 2012;4(2):191-7doi: 10.4161/derm.20332.
Grossmann, R. E., Zughaier, S. M., Kumari, M., Seydafkan, S., Lyles, R. H., Liu, S., Sueblinvong, V., Schechter, M. S., Stecenko, A. A., Ziegler, T. R., & Tangpricha, V. (2012). Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial. Dermato-endocrinology, 4(2), 191-7. https://doi.org/10.4161/derm.20332
Grossmann, Ruth E, et al. "Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial." Dermato-endocrinology vol. 4,2 (2012): 191-7. doi: https://doi.org/10.4161/derm.20332
Grossmann RE, Zughaier SM, Kumari M, Seydafkan S, Lyles RH, Liu S, Sueblinvong V, Schechter MS, Stecenko AA, Ziegler TR, Tangpricha V. Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial. Dermatoendocrinol. 2012 Apr 01;4(2):191-7. doi: 10.4161/derm.20332. PMID: 22928076; PMCID: PMC3427199.
Copy Download .nbib Format: NLM
Mortality Prediction Utilizing Blood Biomarkers to Predict the Severity of COVID-19 Using Machine Learning Technique.

Diagnostics (Basel, Switzerland)

Rahman T, Al-Ishaq FA, Al-Mohannadi FS, Mubarak RS, Al-Hitmi MH, Islam KR, Khandakar A, Hssain AA, Al-Madeed S, Zughaier SM, Chowdhury MEH.
PMID: 34573923
Diagnostics (Basel). 2021 Aug 31;11(9). doi: 10.3390/diagnostics11091582.

Healthcare researchers have been working on mortality prediction for COVID-19 patients with differing levels of severity. A rapid and reliable clinical evaluation of disease intensity will assist in the allocation and prioritization of mortality mitigation resources. The novelty of...

Cite
Rahman T, Al-Ishaq FA, Al-Mohannadi FS, et al. Mortality Prediction Utilizing Blood Biomarkers to Predict the Severity of COVID-19 Using Machine Learning Technique. Diagnostics (Basel). 2021;11(9)doi: 10.3390/diagnostics11091582.
Rahman, T., Al-Ishaq, F. A., Al-Mohannadi, F. S., Mubarak, R. S., Al-Hitmi, M. H., Islam, K. R., Khandakar, A., Hssain, A. A., Al-Madeed, S., Zughaier, S. M., & Chowdhury, M. E. H. (2021). Mortality Prediction Utilizing Blood Biomarkers to Predict the Severity of COVID-19 Using Machine Learning Technique. Diagnostics (Basel, Switzerland), 11(9), . https://doi.org/10.3390/diagnostics11091582
Rahman, Tawsifur, et al. "Mortality Prediction Utilizing Blood Biomarkers to Predict the Severity of COVID-19 Using Machine Learning Technique." Diagnostics (Basel, Switzerland) vol. 11,9 (2021). doi: https://doi.org/10.3390/diagnostics11091582
Rahman T, Al-Ishaq FA, Al-Mohannadi FS, Mubarak RS, Al-Hitmi MH, Islam KR, Khandakar A, Hssain AA, Al-Madeed S, Zughaier SM, Chowdhury MEH. Mortality Prediction Utilizing Blood Biomarkers to Predict the Severity of COVID-19 Using Machine Learning Technique. Diagnostics (Basel). 2021 Aug 31;11(9). doi: 10.3390/diagnostics11091582. PMID: 34573923; PMCID: PMC8469072.
Copy Download .nbib Format: NLM
The Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC) trial: Rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis.

Contemporary clinical trials communications

Tangpricha V, Smith EM, Binongo J, Judd SE, Ziegler TR, Walker S, Tirouvanziam R, Zughaier SM, Lee MJ, Chesdachai S, Hermes WA, Chmiel JF, Gaggar A, Grossmann RE, Joseph PM, Alvarez JA.
PMID: 28508087
Contemp Clin Trials Commun. 2017 Jun;6:39-45. doi: 10.1016/j.conctc.2017.02.010. Epub 2017 Mar 09.

Vitamin D deficiency is highly prevalent in children and adults with cystic fibrosis (CF). Recent studies have found an association between vitamin D status and risk of pulmonary exacerbations in children and adults with CF. The ongoing Vitamin D...

Cite
Tangpricha V, Smith EM, Binongo J, et al. The Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC) trial: Rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis. Contemp Clin Trials Commun. 2017;6:39-45doi: 10.1016/j.conctc.2017.02.010.
Tangpricha, V., Smith, E. M., Binongo, J., Judd, S. E., Ziegler, T. R., Walker, S., Tirouvanziam, R., Zughaier, S. M., Lee, M. J., Chesdachai, S., Hermes, W. A., Chmiel, J. F., Gaggar, A., Grossmann, R. E., Joseph, P. M., & Alvarez, J. A. (2017). The Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC) trial: Rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis. Contemporary clinical trials communications, 639-45. https://doi.org/10.1016/j.conctc.2017.02.010
Tangpricha, Vin, et al. "The Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC) trial: Rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis." Contemporary clinical trials communications vol. 6 (2017): 39-45. doi: https://doi.org/10.1016/j.conctc.2017.02.010
Tangpricha V, Smith EM, Binongo J, Judd SE, Ziegler TR, Walker S, Tirouvanziam R, Zughaier SM, Lee MJ, Chesdachai S, Hermes WA, Chmiel JF, Gaggar A, Grossmann RE, Joseph PM, Alvarez JA. The Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC) trial: Rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis. Contemp Clin Trials Commun. 2017 Jun;6:39-45. doi: 10.1016/j.conctc.2017.02.010. Epub 2017 Mar 09. PMID: 28508087; PMCID: PMC5427007.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16 entries